2023-02-012024-01-312024-01-31false12601353BALANCED HEALTH SOUTHWEST LTD2024-07-05iso4217:GBPxbrli:pure126013532023-02-01126013532024-01-31126013532023-02-012024-01-31126013532022-06-01126013532023-01-31126013532022-06-012023-01-3112601353bus:SmallEntities2023-02-012024-01-3112601353bus:AuditExempt-NoAccountantsReport2023-02-012024-01-3112601353bus:FullAccounts2023-02-012024-01-3112601353bus:PrivateLimitedCompanyLtd2023-02-012024-01-3112601353core:WithinOneYear2024-01-3112601353core:AfterOneYear2024-01-3112601353core:WithinOneYear2023-01-3112601353core:AfterOneYear2023-01-3112601353core:ShareCapital2024-01-3112601353core:SharePremium2024-01-3112601353core:RevaluationReserve2024-01-3112601353core:OtherReservesSubtotal2024-01-3112601353core:RetainedEarningsAccumulatedLosses2024-01-3112601353core:ShareCapital2023-01-3112601353core:SharePremium2023-01-3112601353core:RevaluationReserve2023-01-3112601353core:OtherReservesSubtotal2023-01-3112601353core:RetainedEarningsAccumulatedLosses2023-01-3112601353core:LandBuildings2024-01-3112601353core:PlantMachinery2024-01-3112601353core:Vehicles2024-01-3112601353core:FurnitureFittings2024-01-3112601353core:OfficeEquipment2024-01-3112601353core:NetGoodwill2024-01-3112601353core:IntangibleAssetsOtherThanGoodwill2024-01-3112601353core:ListedExchangeTraded2024-01-3112601353core:UnlistedNon-exchangeTraded2024-01-3112601353core:LandBuildings2023-01-3112601353core:PlantMachinery2023-01-3112601353core:Vehicles2023-01-3112601353core:FurnitureFittings2023-01-3112601353core:OfficeEquipment2023-01-3112601353core:NetGoodwill2023-01-3112601353core:IntangibleAssetsOtherThanGoodwill2023-01-3112601353core:ListedExchangeTraded2023-01-3112601353core:UnlistedNon-exchangeTraded2023-01-3112601353core:LandBuildings2023-02-012024-01-3112601353core:PlantMachinery2023-02-012024-01-3112601353core:Vehicles2023-02-012024-01-3112601353core:FurnitureFittings2023-02-012024-01-3112601353core:OfficeEquipment2023-02-012024-01-3112601353core:NetGoodwill2023-02-012024-01-3112601353core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3112601353core:ListedExchangeTraded2023-02-012024-01-3112601353core:UnlistedNon-exchangeTraded2023-02-012024-01-3112601353core:MoreThanFiveYears2023-02-012024-01-3112601353core:Non-currentFinancialInstruments2024-01-3112601353core:Non-currentFinancialInstruments2023-01-3112601353dpl:CostSales2023-02-012024-01-3112601353dpl:DistributionCosts2023-02-012024-01-3112601353core:LandBuildings2023-02-012024-01-3112601353core:PlantMachinery2023-02-012024-01-3112601353core:Vehicles2023-02-012024-01-3112601353core:FurnitureFittings2023-02-012024-01-3112601353core:OfficeEquipment2023-02-012024-01-3112601353dpl:AdministrativeExpenses2023-02-012024-01-3112601353core:NetGoodwill2023-02-012024-01-3112601353core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3112601353dpl:GroupUndertakings2023-02-012024-01-3112601353dpl:ParticipatingInterests2023-02-012024-01-3112601353dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-012024-01-3112601353core:ListedExchangeTraded2023-02-012024-01-3112601353dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-012024-01-3112601353core:UnlistedNon-exchangeTraded2023-02-012024-01-3112601353dpl:CostSales2022-06-012023-01-3112601353dpl:DistributionCosts2022-06-012023-01-3112601353core:LandBuildings2022-06-012023-01-3112601353core:PlantMachinery2022-06-012023-01-3112601353core:Vehicles2022-06-012023-01-3112601353core:FurnitureFittings2022-06-012023-01-3112601353core:OfficeEquipment2022-06-012023-01-3112601353dpl:AdministrativeExpenses2022-06-012023-01-3112601353core:NetGoodwill2022-06-012023-01-3112601353core:IntangibleAssetsOtherThanGoodwill2022-06-012023-01-3112601353dpl:GroupUndertakings2022-06-012023-01-3112601353dpl:ParticipatingInterests2022-06-012023-01-3112601353dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-01-3112601353core:ListedExchangeTraded2022-06-012023-01-3112601353dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-01-3112601353core:UnlistedNon-exchangeTraded2022-06-012023-01-3112601353core:NetGoodwill2024-01-3112601353core:IntangibleAssetsOtherThanGoodwill2024-01-3112601353core:LandBuildings2024-01-3112601353core:PlantMachinery2024-01-3112601353core:Vehicles2024-01-3112601353core:FurnitureFittings2024-01-3112601353core:OfficeEquipment2024-01-3112601353core:AfterOneYear2024-01-3112601353core:WithinOneYear2024-01-3112601353core:ListedExchangeTraded2024-01-3112601353core:UnlistedNon-exchangeTraded2024-01-3112601353core:ShareCapital2024-01-3112601353core:SharePremium2024-01-3112601353core:RevaluationReserve2024-01-3112601353core:OtherReservesSubtotal2024-01-3112601353core:RetainedEarningsAccumulatedLosses2024-01-3112601353core:NetGoodwill2023-01-3112601353core:IntangibleAssetsOtherThanGoodwill2023-01-3112601353core:LandBuildings2023-01-3112601353core:PlantMachinery2023-01-3112601353core:Vehicles2023-01-3112601353core:FurnitureFittings2023-01-3112601353core:OfficeEquipment2023-01-3112601353core:AfterOneYear2023-01-3112601353core:WithinOneYear2023-01-3112601353core:ListedExchangeTraded2023-01-3112601353core:UnlistedNon-exchangeTraded2023-01-3112601353core:ShareCapital2023-01-3112601353core:SharePremium2023-01-3112601353core:RevaluationReserve2023-01-3112601353core:OtherReservesSubtotal2023-01-3112601353core:RetainedEarningsAccumulatedLosses2023-01-3112601353core:NetGoodwill2022-06-0112601353core:IntangibleAssetsOtherThanGoodwill2022-06-0112601353core:LandBuildings2022-06-0112601353core:PlantMachinery2022-06-0112601353core:Vehicles2022-06-0112601353core:FurnitureFittings2022-06-0112601353core:OfficeEquipment2022-06-0112601353core:AfterOneYear2022-06-0112601353core:WithinOneYear2022-06-0112601353core:ListedExchangeTraded2022-06-0112601353core:UnlistedNon-exchangeTraded2022-06-0112601353core:ShareCapital2022-06-0112601353core:SharePremium2022-06-0112601353core:RevaluationReserve2022-06-0112601353core:OtherReservesSubtotal2022-06-0112601353core:RetainedEarningsAccumulatedLosses2022-06-0112601353core:AfterOneYear2023-02-012024-01-3112601353core:WithinOneYear2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:CostValuation2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3112601353core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3112601353core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3112601353core:Non-currentFinancialInstrumentscore:CostValuation2023-01-3112601353core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-3112601353core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-3112601353core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-3112601353core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-3112601353core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-3112601353core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-3112601353core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-3112601353core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-3112601353bus:Director12023-02-012024-01-3112601353bus:Director22023-02-012024-01-31

BALANCED HEALTH SOUTHWEST LTD

Registered Number
12601353
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2024

BALANCED HEALTH SOUTHWEST LTD
Company Information
for the year from 1 February 2023 to 31 January 2024

Directors

Dr Ian David Strawford
Natalie Tandy

Registered Address

Flat 49 17 Marrowbone Slip
Plymouth
PL4 0HX

Registered Number

12601353 (England and Wales)
BALANCED HEALTH SOUTHWEST LTD
Balance Sheet as at
31 January 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets3137,6671,252
137,6671,252
Current assets
Debtors707,916167
Cash at bank and on hand65,8552,344
773,7712,511
Creditors amounts falling due within one year4(12,692)(4,928)
Net current assets (liabilities)761,079(2,417)
Total assets less current liabilities898,746(1,165)
Net assets898,746(1,165)
Capital and reserves
Called up share capital210200
Profit and loss account898,536(1,365)
Shareholders' funds898,746(1,165)
The financial statements were approved and authorised for issue by the Board of Directors on 5 July 2024, and are signed on its behalf by:
Dr Ian David Strawford
Director
Registered Company No. 12601353
BALANCED HEALTH SOUTHWEST LTD
Notes to the Financial Statements
for the year ended 31 January 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Dividend income
Dividend income is recognised when the right to receive payment is established.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)Straight line (years)
Vehicles25-
Office Equipment253
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

20242023
Average number of employees during the year22
3.Tangible fixed assets

Plant & machinery

Vehicles

Office Equipment

Total

££££
Cost or valuation
At 01 February 23--2,0872,087
Additions-21,538146,463168,001
At 31 January 24-21,538148,550170,088
Depreciation and impairment
At 01 February 23--835835
Charge for year31,586--31,586
At 31 January 2431,586-83532,421
Net book value
At 31 January 24(31,586)21,538147,715137,667
At 31 January 23--1,2521,252
4.Creditors: amounts due within one year

2024

2023

££
Amounts owed to related parties-4,333
Taxation and social security12,692-
Other creditors-595
Total12,6924,928
5.Related party transactions
At the year end Dr I Strawford, Director, owed the company £457,507 (2022 - was owed £594). At the year end Mrs N Tandy, Director, owed the company £5,802 (2022 owed £49). At the year end the company was owed by Skin Excellence Clinics Ltd, a related company, £231,899 (2022 - the company owed Skin Excellence Clinics Ltd £4,333).
6.Parent-subsidiary relationships
This company owns 100% of Skin Excellence Clinics Ltd.